Q: Hi 5i Aurinia pharma seems to have turned the corner with earnings and is also getting the drug into hospitals They are again reducing staff this time by 45%. They also have a new drug in trails. Please put on your speculative hat for the questions.
-would drug (Lupkynis) be of interest at this stage in development for another company to buy them and what would the buyout price be for the right company.
-going forward they will make about $220,000,000 a year this took about 3 1/2 years with a covid launch, what do you see max sale's being with the current set up and how many years to get there.
-Do you think Aurinia is a good speculative buy.
Thank you for your service!
-would drug (Lupkynis) be of interest at this stage in development for another company to buy them and what would the buyout price be for the right company.
-going forward they will make about $220,000,000 a year this took about 3 1/2 years with a covid launch, what do you see max sale's being with the current set up and how many years to get there.
-Do you think Aurinia is a good speculative buy.
Thank you for your service!
Q: Hi 5i,
How do you feel about Aurinia, hey will be cashflow positive soon. Recently they announced a 150 million buy back with a 25% staff reduction. They are also ending a strategic review. Sales are ramping up looks like a timely buy with share price at a low. Your thoughts are appreciated.
How do you feel about Aurinia, hey will be cashflow positive soon. Recently they announced a 150 million buy back with a 25% staff reduction. They are also ending a strategic review. Sales are ramping up looks like a timely buy with share price at a low. Your thoughts are appreciated.
Q: Hi 5i, this company recently tried to sell itself and there were no takers. They now have decided to let go of 25% of the workforce and buy up to 150 million dollars of shares back.
Looks like they will be cash flow positive by next quarter and are starting to get better traction on selling the drug.
The drug patent is for dosing as the chemical composition expires in a couple years. How would you value this company and would you rate it a buy hold or sell.
Looks like they will be cash flow positive by next quarter and are starting to get better traction on selling the drug.
The drug patent is for dosing as the chemical composition expires in a couple years. How would you value this company and would you rate it a buy hold or sell.